CABA stock icon

Cabaletta Bio
CABA

$12.16
12.47%
 

About: Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

Employees: 120

0
Funds holding %
of 6,689 funds
0
Analysts bullish %
of 8 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

193% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 15

23% more funds holding

Funds holding: 127 [Q4 2023] → 156 (+29) [Q1 2024]

2% less repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 47

7.51% less ownership

Funds ownership: 113.28% [Q4 2023] → 105.77% (-7.51%) [Q1 2024]

21% less capital invested

Capital invested by funds: $1.1B [Q4 2023] → $870M (-$231M) [Q1 2024]

51% less call options, than puts

Call options by funds: $6.8M | Put options by funds: $14M

60% less funds holding in top 10

Funds holding in top 10: 5 [Q4 2023] → 2 (-3) [Q1 2024]

Research analyst outlook

8 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$30
147%
upside
Avg. target
$36
199%
upside
High target
$50
311%
upside

8 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Douglas Tsao
147%upside
$30
Buy
Reiterated
24 May 2024
HC Wainwright & Co.
Douglas Tsao
147%upside
$30
Buy
Reiterated
16 May 2024
Cantor Fitzgerald
Joshua Schimmer
311%upside
$50
Overweight
Reiterated
5 Apr 2024
Citigroup
Samantha Semenkow
147%upside
$30
Buy
Maintained
4 Apr 2024
Cantor Fitzgerald
Joshua Schimmer
311%upside
$50
Overweight
Reiterated
22 Mar 2024

Financial journalist opinion